Trial Profile
Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable adenocarcinoma of the gastroesophageal junction or stomach (HerFLOT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms HerFLOT
- 15 Sep 2021 Primary endpoint has been met. (Rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference pathologist.), as per Results published in the International Journal of Cancer
- 15 Sep 2021 Results published in the International Journal of Cancer
- 16 Jun 2017 Status changed from active, no longer recruiting to completed.